TermGallery
Anglès
Anglès
Espanyol
Català
Portuguès
Rus
CA
English
Español
Català
Português
Русский
1
Purpose: Chemotherapy-induced
gastrointestinal
toxicity
is a common adverse event during chemotherapeutic treatment.
2
No uniformly applicable strategies exist to predict, prevent, or treat
gastrointestinal
toxicity
.
3
Acute
gastrointestinal
toxicity
was scored according to the Radiation Therapy Oncology Group criteria.
4
Treatment was not significantly more complex nor was
gastrointestinal
toxicity
increased.
5
Toxicities were acceptable and consisted primarily of leukopenia and
gastrointestinal
toxicity
.
6
At these doses, no Grade 3 or higher acute
gastrointestinal
toxicity
was observed.
7
There were no episodes of cystitis and
gastrointestinal
toxicity
was moderate.
8
Conclusions: Dose escalation had to be stopped early because of
gastrointestinal
toxicity
and fatigue.
9
This treatment schedule is associated with mild myelosuppression and mild to moderate
gastrointestinal
toxicity
.
10
Side effects of induction-phase I were predominantly hematological with subsequent infections and
gastrointestinal
toxicity
.
11
The recommended dose to achieve local control without significant acute
gastrointestinal
toxicity
is 25 Gy.
12
However, increased dose intensity of bortezomib led to increased
gastrointestinal
toxicity
as well as myelosuppression.
13
In clinical trials the combination of the two agents was associated with increased
gastrointestinal
toxicity
.
14
Only
gastrointestinal
toxicity
World Health grade I occurred.
15
Significant toxicity occurred in 60% of patients, predominantly
gastrointestinal
toxicity
and bone marrow suppression.
16
In conclusion, CEP-701 resulted in modest efficacy and mild but frequent
gastrointestinal
toxicity
in MF patients.
gastrointestinal
toxicity
gastrointestinal